Browsing by Author "Ibanda, Ivan"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Antinociceptive and anti-inflammatory activities of the aqueous leaf extract of Erlangea tomentosa (Asteraceae) in rats and mice
    (Journal of Pharmacy & Bioresources, 2020) Muhwana, Isaac; Obakiro, Samuel Baker; Ibanda, Ivan; Crucifix, Pender Gift; Moyosore Afodun, Adam; Odoma, Saidi
    Erlangea tomentosa (Asteraceae) is used traditionally in the preparation of herbal remedies for management of several diseases including pain and inflammation. However, its efficacy and safety have not been scientifically validated. The aim of this study was to investigate the antinociceptive and anti-inflammatory activities of the aqueous leaf extract of this plant and its acute toxicity profile in animal models. Antinociceptive activity and anti-inflammatory activity were determined using the acetic acid-induced writhing model in mice and carrageenan induced inflammation model in rats respectively. The oral median lethal dose (LD50) was determined using the Lorke’s Method. The extract inhibited pain due to acetic acid significantly (p<0.05) at doses of 250 mg/kg and 500 mg/kg. The inflammation due to carrageenan was also significantly (p<0.05) reduced at dose of 500 mg/kg body weight but not 250 mg/Kg. The LD50 value of the extract was greater than 5,000 mg/kg implying that the extract was safe in 24 hours when administered in a single high oral dose. Preliminary phytochemical screening revealed the presence of alkaloids, anthraquinones, coumarins, saponins, tannins and resins. The present study has demonstrated the antinociceptive and anti-inflammatory potential of aqueous leaf extract of Erlangea tomentosa in rats and mice; thus validates the folkloric use of the plant.
  • Thumbnail Image
    Item
    Operationalization of COVID-19 Rapid Diagnosis Using Xpert® Xpress SARS CoV-2 Assay in Resource-Limited Settings: Early Implementation Lessons From Uganda
    (Research Square, 2021) Nsawotebba, Andrew; Ibanda, Ivan; Ssentalo Bagaya, Bernard; Nyombi, Abdunoor; Kagirita, Atek; Tugumisirize, Didas; Mujuni, Dennis; Majwala, Robert Kaos; Ocen, Francis; Kabugo, Joel; Adam, Isa; Wekiya, Enock; Munduku, Benoni; Linda, Lillian; Kalyesubula-Kibuuka, Simon; Okiira, Christopher; Kigozi, Edgar; Ogwok, Patrick; Lutakoome Joloba, Moses; Nabadda, Susan; Ssengooba, Willy
    The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease is a global challenge. Several countries have adopted testing, isolation, and tracing strategy towards the control of the COVID-19 pandemic, but access to rapid and accurate testing is still a global challenge. The conventional PCR – based assay is the most commonly used test yet it has huge costs, infrastructural, and procurement logistical challenges. The Xpert® Xpress SARS-CoV-2 test is an automated in – vitro diagnostic test for the qualitative detection of nucleic acid from SARS-CoV-2 within a turnaround time of 60 minutes on the widely used GeneXpert Dx Instrument Systems. Here we document the best practices and challenges encountered with the operationalization of Xpert® Xpress SARS-CoV-2 testing in a resource-limited setting. Materials and Methods: The Xpert® Xpress SARS-CoV-2 implementation followed an operational work plan that included; Laboratory COVID-19 policy and planning, situational analysis of the Laboratory network, country Xpert® Xpress SARS-CoV-2 assay verification, and rollout at Mutukula Port Health Laboratory. The Laboratory strategy was based on a set of six objectives; conducting infrastructural modifications, building a strong COVID-19 testing capacity, developing robust Laboratory Quality and Information Management Systems, establishing a Bio-risk management and Bio-banking capacity.